Agnieszka Giza
Overview
Explore the profile of Agnieszka Giza including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Jurczak W, Ramanathan S, Giri P, Romano A, Mocikova H, Clancy J, et al.
Leuk Lymphoma
. 2017 Aug;
59(3):670-678.
PMID: 28768446
Temsirolimus 175 mg once-weekly for 3 weeks, followed by 75 mg once-weekly intravenously dosed (175/75 mg) is approved in the European Union for treatment of relapsed/refractory mantle cell lymphoma (MCL)....
22.
Kocurek A, Malkowski B, Giza A, Jurczak W
Contemp Oncol (Pozn)
. 2016 Oct;
20(4):297-301.
PMID: 27688726
Aim Of The Study: Determining the role of PET/CT imaging in the evaluation of treatment efficacy in primary mediastinal B-cell lymphoma (PMBCL). Material And Methods: Retrospective analysis of seven PMBCL...
23.
Kucharz J, Giza A, Dumnicka P, Kuzniewski M, Kusnierz-Cabala B, Bryniarski P, et al.
Med Oncol
. 2016 Aug;
33(10):109.
PMID: 27573381
Sunitinib, a multi-targeted receptor tyrosine kinase inhibitor, is a first-line treatment for metastatic renal cell carcinoma (mRCC) in patients in 'low' and 'intermediate' Memorial Sloan Kettering Cancer Center and Heng...
24.
Jurczyszyn A, Vesole D, Gdula-Argasinska J, Giza A, Zawirska D, Baster J, et al.
Przegl Lek
. 2016 Mar;
72(11):606-10.
PMID: 27012116
The use of the combination of two cytostatics cyclophosphamide (CTX) and etoposide (VEP) and G-CSF is a reasonable alternative, especially for stem mobilization in multiple myeloma (MM) patients from countries...
25.
Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al.
Lancet Oncol
. 2016 Feb;
17(3):319-331.
PMID: 26899778
Background: Lenalidomide, an immunomodulatory drug with antineoplastic and antiproliferative effects, showed activity in many single-group studies in relapsed or refractory mantle cell lymphoma. The aim of this randomised study was...
26.
Rybka J, Jurczak W, Giza A, Paszkiewicz-Kozik E, Kumiega B, Drozd-Sokolowska J, et al.
Adv Clin Exp Med
. 2016 Jan;
24(5):783-9.
PMID: 26768628
Background: The treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains challenging. Gemcitabine is a cytidine analog with a wide spectrum of antitumor activity....
27.
Jurczak W, Ochrem B, Giza A, Zimowska-Curylo D, Gorecki T, Boguradzki P, et al.
Pol Arch Med Wewn
. 2015 Sep;
125(10):741-8.
PMID: 26334344
Introduction: R-CHOP immunochemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) is a standard first-line treatment for diffuse large B-cell lymphoma (DLBCL). None of the randomized trials have proved a statistically significant overall...
28.
Jurczak W, Kroll-Balcerzak R, Giebel S, Machaczka M, Giza A, Ogorka T, et al.
Med Oncol
. 2015 Feb;
32(4):90.
PMID: 25716885
Lymphomas with primary or secondary involvement of central nervous system (CNS) have poor prognosis despite specific treatment protocols which include whole brain radiotherapy and high-dose systemic and/or intrathecal chemotherapy. Toxicity...
29.
Sokolowska-Wojdylo M, Florek A, Zaucha J, Chmielowska E, Giza A, Knopinska-Posluszny W, et al.
Am J Ther
. 2014 Apr;
23(3):e749-56.
PMID: 24732904
Bexarotene, a synthetic retinoid licensed for the treatment of refractory cutaneous T-cell lymphoma (CTCL), has been used clinically in Poland since 2007 in 21 patients. The objective of our retrospective,...
30.
Jurczak W, Krochmalczyk D, Giza A, Sobocinski M, Skotnicki A
Przegl Lek
. 2012 Oct;
69(5):171-5.
PMID: 23050411
Hodgkin Disease is one of the common lymphoma subtypes: every year over 750 new cases are diagnosed in Poland. It is most frequent in young adults between 25 - 30...